Αρχειοθήκη ιστολογίου

Παρασκευή 9 Ιουνίου 2017

Alectinib Touted as New Standard of Care for ALK-Positive Lung Cancer

The second-generation ALK-inhibitor alectinib should be the new standard of care for first-line treatment of ALK-positive non –small-cell lung cancer, according to a new study. (Source: CancerNetwork)

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r2vurB
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader